We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2021 to May 2024
By Dave Sebastian
Merck & Co. said two Phase 3 trials of a combination pill for adults with HIV-1 infection met their primary efficacy endpoint.
The drugmaker on Monday said that at 48 weeks, the trials met their safety and efficacy endpoints in adults with HIV-1 infection currently on antiretroviral therapy. The endpoint is defined as a percentage of participants with HIV-1 RNA levels of more than 50 copies per milliliter, the company said.
Merck said the first trial evaluated a switch from antiretroviral therapy to doravirine/islatravir. The second trial evaluated a switch from bictegravir/emtricitabine/tenofovir to doravirine/islatravir, the company said.
Merck said it will present detailed findings from the studies at a future scientific congress.
"We will continue to study doravirine/islatravir in diverse populations of people living with HIV and look forward to sharing data from these trials," said Joan Butterton, a vice president at Merck Research Laboratories.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 25, 2021 07:30 ET (11:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
